Evidence method
Level · gp.fundamentals.debt_to_revenue
986.10% · OPTIONAL · NOT_ENOUGH_HISTORY
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Mar 31, 2022
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-22-008990General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.70% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-1157.30% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-35.61% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-1423.80% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
1008.20% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
301.10% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesSelf-history eligible
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 6.11%
- Current
- 2.70%
- Delta
- -3.41%
- Previous
- -259.93%
- Current
- -1157.30%
- Delta
- -897.37%
- Previous
- 373.68%
- Current
- -35.61%
- Delta
- -409.29%
- Previous
- -292.56%
- Current
- -1423.80%
- Delta
- -1131.24%
- Previous
- 276.73%
- Current
- 1008.20%
- Delta
- 731.47%
- Previous
- 77.07%
- Current
- 301.10%
- Delta
- 224.03%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Analogous To · CUE state analogue 3 →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE CAPEX_INTENSITY_DECREASED →Transitioned To · CUE CASH_GENERATION_DECREASED →Transitioned To · CUE GROWTH_DECREASED →Transitioned To · CUE PROFITABILITY_DECREASED →Transitioned To · CUE R_AND_D_INTENSITY_INCREASED →Transitioned To · CUE SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.